187 related articles for article (PubMed ID: 30578958)
1. Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?
Di Veroli A; Campagna A; De Muro M; Maurillo L; Trawinska MM; LeonettiCrescenzi S; Petriccione L; Romano A; D'Addosio A; Cenfra A; Montanaro M; Felici S; Andriani A; Carmosino I; Niscola P; Montefusco E; Breccia M; Latagliata R
Leuk Res; 2019 Jan; 76():65-69. PubMed ID: 30578958
[TBL] [Abstract][Full Text] [Related]
2. Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.
Latagliata R; Montagna C; Porrini R; Di Veroli A; Leonetti SC; Niscola P; Ciccone F; Spadea A; Breccia M; Maurillo L; Rago A; Spirito F; Cedrone M; De Muro M; Montanaro M; Andriani A; Bagnato A; Montefusco E; Alimena G
Eur J Haematol; 2016 Jun; 96(6):643-9. PubMed ID: 26277477
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.
Nolte F; Nückel H; Schmidt B; Geer T; Rubanov O; Hebart H; Jarisch A; Albrecht S; Johr C; Schumann C; Hofmann WK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1531-1538. PubMed ID: 29761371
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).
Antmen B; Karakaş Z; Yeşilipek MA; Küpesiz OA; Şaşmaz İ; Uygun V; Kurtoğlu E; Oktay G; Aydogan G; Akın M; Salcioglu Z; Vergin C; Kazancı EG; Ünal S; Çalışkan Ü; Aral YZ; Türkkan E; Meral Güneş A; Tunç B; Gümrük F; Ayhan AC; Söker M; Koç A; Oymak Y; Ertem M; Timur Ç; Yıldırmak Y; İrken G; Apak H; Biner B; Eren TG; Işık Balcı Y; Koçak Ü; Karasu G; Akkaynak D; Patıroğlu T
Eur J Haematol; 2019 Feb; 102(2):123-130. PubMed ID: 30300449
[TBL] [Abstract][Full Text] [Related]
5. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
[TBL] [Abstract][Full Text] [Related]
7. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
Maurillo L; Breccia M; Buccisano F; Voso MT; Niscola P; Trapè G; Tatarelli C; D'Addosio A; Latagliata R; Fenu S; Piccioni AL; Fragasso A; Aloe Spiriti MA; Refrigeri M; Criscuolo M; Musto P; Venditti A
Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
[TBL] [Abstract][Full Text] [Related]
8. A 15-years follow-up of deferasirox in beta-thalassaemia major patients with iron overload.
Wei Z; Yang G; Huang Y; Peng P; Long L; Long Y; Huang X; Zhou X; Lai Y; Liu R
Br J Haematol; 2020 Nov; 191(3):e81-e83. PubMed ID: 32945527
[No Abstract] [Full Text] [Related]
9. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Chen CH; Shu KH; Yang Y
Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
[TBL] [Abstract][Full Text] [Related]
10. Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
Watanabe J; Sato K; Horiuchi T; Kato S; Hikota R; Maekawa T; Yamamura T; Kobayashi A; Osawa Y; Kobayashi S; Kimura F
Int J Hematol; 2014 Sep; 100(3):254-9. PubMed ID: 24986748
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
Dou H; Qin Y; Chen G; Zhao Y
Acta Haematol; 2019; 141(1):32-42. PubMed ID: 30504715
[TBL] [Abstract][Full Text] [Related]
12. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
14. Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study.
Taher AT; Wali Y; Cruz MC; Charoenkwan P; Aydinok Y; Werner O; Govindaraju S; Romen F; Viprakasit V
Haematologica; 2024 May; 109(5):1413-1425. PubMed ID: 37855069
[TBL] [Abstract][Full Text] [Related]
15. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network.
Tsouana E; Kaya B; Gadong N; Hemmaway C; Newell H; Simmons A; Whitmarsh S; Telfer P
Eur J Haematol; 2015 Apr; 94(4):336-42. PubMed ID: 25138173
[TBL] [Abstract][Full Text] [Related]
17. Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients.
Pinto VM; Balocco M; Quintino S; Bacigalupo L; Gianesin B; Rizzi M; Malagò R; De Franceschi L; Forni GL
Am J Hematol; 2018 Oct; 93(10):E338-E340. PubMed ID: 30033633
[No Abstract] [Full Text] [Related]
18. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
Kattamis A; Aydinok Y; Taher A
Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
[TBL] [Abstract][Full Text] [Related]
19. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
20. No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
Saleem A; Waqar E; Shuja SH; Naeem U; Moeed A; Rais H; Ahmed J
Transfus Clin Biol; 2023 Feb; 30(1):69-74. PubMed ID: 35878782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
